Gastrointestinal Surgery| Volume 286, P41-48, June 2023

Download started.


Impact on Cardiovascular Health of Using Phentermine/Topiramate in Combination With Laparoscopic Sleeve Gastrectomy in Super Obesity

Published:February 06, 2023DOI:


      • We studied blood pressure effects of Phentermine/Topiramate and Sleeve Gastrectomy.
      • Blood pressure improved with use of Phentermine/Topiramate with Sleeve Gastrectomy.
      • Antihypertensives were not needed with Sleeve Gastrectomy and Phentermine/Topiramate.
      • 41% of patients with Sleeve Gastrectomy alone continued antihypertensive medication.



      Management of patients with BMI≥50 kg/m2 is challenging. In previous work, pre and postoperative pharmacotherapy with phentermine/topiramate plus laparoscopic sleeve gastrectomy (PT + SG) promoted greater weight loss than sleeve gastrectomy (SG) alone at 24 mo postoperatively. This current secondary analysis studied the impact of PT + SG on blood pressure (BP), heart rate, and antihypertensive usage.


      Patients with BMI≥50 kg/m2 planning to have SG (n = 13) were recruited from 2014 to 2016, at an academic medical center in Winston–Salem, North Carolina, for this open-label trial. Participants took phentermine/topiramate (PT; 7.5/46–15/92 mg/d) for ≥3 mo preoperatively and 24 mo postoperatively. The control group (n = 40) underwent SG during the same time frame. We used mixed models for BP and heart rate to compare PT + SG versus SG alone over time, adjusted for age, sex, and initial BP.


      By 24 mo postoperatively the model adjusted changes in systolic blood pressure/diastolic blood pressure (SBP/DBP) (mm Hg) were −24.44 (−34.46,−14.43)/−28.60 (−40.74,−16.46) in the PT + SG group versus −11.81 (−17.58,−6.05)/−13.89 (−21.32,−6.46) in the control group (SBP P = 0.02; DBP P = 0.03). At baseline 8 (61.5%) participants in the PT + SG arm and 22 (55.0%) in the control group used antihypertensives. Excluding patients lost to follow-up (n = 3), by 24 mo postoperatively, none of the PT + SG participants were on antihypertensives compared to 14 (41.2%) in the control group (P = 0.01).


      Patients with BMI≥50 kg/m2 treated with PT + SG had greater improvement in BP with no use of antihypertensive medication at 24 mo postoperatively versus SG alone, where 41% continued medication use. Larger trials are required to evaluate this.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Surgical Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Sturm R.
        • Hattori A.
        Morbid obesity rates continue to rise rapidly in the United States.
        Int J Obes. 2013; 37: 889-891
        • Collins J.
        • McCloskey C.
        • Titchner R.
        • et al.
        Preoperative weight loss in high-risk superobese bariatric patients: a computed tomography-based analysis.
        Surg Obes Relat Dis. 2011; 7: 480-485
        • Nasser H.
        • Ivanics T.
        • Leonard-Murali S.
        • Shakaroun D.
        • Genaw J.
        Perioperative outcomes of laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy in super-obese and super-super-obese patients: a national database analysis.
        Surg Obes Relat Dis. 2019; 15: 1696-1703
        • Lee Y.
        • Dang J.T.
        • Switzer N.
        • Malhan R.
        • Birch D.W.
        • Karmali S.
        Bridging interventions before bariatric surgery in patients with BMI ≥ 50 kg/m2: a systematic review and meta-analysis.
        Surg Endosc. 2019; 33: 3578-3588
        • Santo M.A.
        • Riccioppo D.
        • Pajecki D.
        • Cleva R de
        • Kawamoto F.
        • Cecconello I.
        Preoperative weight loss in super-obese patients: study of the rate of weight loss and its effects on surgical morbidity.
        Clin Sao Paulo Braz. 2014; 69: 828-834
        • Bhandari M.
        • Ponce de Leon-Ballesteros G.
        • Kosta S.
        • et al.
        Surgery in patients with super obesity: medium-term follow-up outcomes at a high-volume center.
        Obes Silver Spring Md. 2019; 27: 1591-1597
        • Maciejewski M.L.
        • Patrick D.L.
        • Williamson D.F.
        A structured review of randomized controlled trials of weight loss showed little improvement in health-related quality of life.
        J Clin Epidemiol. 2005; 58: 568-578
        • C Sudlow A.
        • W le Roux C.
        • J Pournaras D.
        Review of advances in anti-obesity pharmacotherapy: implications for a multimodal treatment approach with metabolic surgery.
        Obes Surg. 2019; 29: 4095-4104
        • Cohen J.B.
        Hypertension in obesity and the impact of weight loss.
        Curr Cardiol Rep. 2017; 19: 98-112
        • Chang S.-H.
        • Stoll C.R.T.
        • Song J.
        • Varela J.E.
        • Eagon C.J.
        • Colditz G.A.
        The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012.
        JAMA Surg. 2014; 149: 275-287
        • Nguyen N.T.
        • Vu S.
        • Kim E.
        • Bodunova N.
        • Phelan M.J.
        Trends in utilization of bariatric surgery, 2009-2012.
        Surg Endosc. 2016; 30: 2723-2727
        • Graham C.
        • Switzer N.
        • Reso A.
        • et al.
        Sleeve gastrectomy and hypertension: a systematic review of long-term outcomes.
        Surg Endosc. 2019; 33: 3001-3007
        • Hariri K.
        • Guevara D.
        • Dong M.
        • Kini S.U.
        • Herron D.M.
        • Fernandez-Ranvier G.
        Is bariatric surgery effective for co-morbidity resolution in the super-obese patients?.
        Surg Obes Relat Dis. 2018; 14: 1261-1268
        • Ard J.D.
        • Beavers D.P.
        • Hale E.
        • Miller G.
        • McNatt S.
        • Fernandez A.
        Use of phentermine-topiramate extended release in combination with sleeve gastrectomy in patients with BMI 50 kg/m2 or more.
        Surg Obes Relat Dis. 2019; 15: 1039-1043
        • Cunningham J.W.
        • Wiviott S.D.
        Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit.
        Clin Cardiol. 2014; 37: 693-699
        • Bray G.A.
        • Heisel W.E.
        • Afshin A.
        • et al.
        The science of obesity management: an endocrine society scientific statement.
        Endocr Rev. 2018; 39: 79-132
        • Bray G.A.
        Lifestyle and pharmacological approaches to weight loss: efficacy and safety.
        J Clin Endocrinol Metab. 2008; 93: S81-S88
        • Siebenhofer A.
        • Horvath K.
        • Jeitler K.
        • et al.
        Long-term effects of weight-reducing drugs in hypertensive patients.
        Cochrane Database Syst Rev. 2009; 3: CD007654
        • Cohen J.B.
        • Gadde K.M.
        Weight loss medications in the treatment of obesity and hypertension.
        Curr Hypertens Rep. 2019; 21: 16-32
        • Hendricks E.J.
        • Greenway F.L.
        • Westman E.C.
        • Gupta A.K.
        Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity.
        Obes Silver Spring Md. 2011; 19: 2351-2360
        • Nor Hanipah Z.
        • Nasr E.C.
        • Bucak E.
        • et al.
        Efficacy of adjuvant weight loss medication after bariatric surgery.
        Surg Obes Relat Dis. 2018; 14: 93-98
        • Stanford F.C.
        • Alfaris N.
        • Gomez G.
        • et al.
        The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: a multi-center study.
        Surg Obes Relat Dis. 2017; 13: 491-500
        • Landsberg L.
        • Aronne L.J.
        • Beilin L.J.
        • et al.
        Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of the Obesity Society and the American Society of Hypertension.
        J Clin Hypertens Greenwich Conn. 2013; 15: 14-33
        • Seravalle G.
        • Colombo M.
        • Perego P.
        • et al.
        Long-term sympathoinhibitory effects of surgically induced weight loss in severe obese patients.
        Hypertens Dallas Tex 1979. 2014; 64: 431-437
        • Thomas C.E.
        • Mauer E.A.
        • Shukla A.P.
        • Rathi S.
        • Aronne L.J.
        Low adoption of weight loss medications: a comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s.
        Obes Silver Spring Md. 2016; 24: 1955-1961
        • Kaplan L.M.
        Pharmacologic therapies for obesity.
        Gastroenterol Clin North Am. 2010; 39: 69-79
        • Apovian C.M.
        • Aronne L.J.
        • Bessesen D.H.
        • et al.
        Pharmacological management of obesity: an endocrine Society clinical practice guideline.
        J Clin Endocrinol Metab. 2015; 100: 342-362
        • Lewis K.H.
        • Fischer H.
        • Ard J.
        • et al.
        Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort.
        Obes Silver Spring Md. 2019; 27: 591-602
        • Jordan J.
        • Astrup A.
        • Engeli S.
        • Narkiewicz K.
        • Day W.W.
        • Finer N.
        Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity.
        J Hypertens. 2014; 32: 1178-1188
        • Alfaris N.
        • Minnick A.M.
        • Hopkins C.M.
        • Berkowitz R.I.
        • Wadden T.A.
        Combination phentermine and topiramate extended release in the management of obesity.
        Expert Opin Pharmacother. 2015; 16: 1263-1274
        • Garvey W.T.
        • Ryan D.H.
        • Look M.
        • et al.
        Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
        Am J Clin Nutr. 2012; 95: 297-308
        • Stanford F.C.
        Controversial issues: a practical guide to the use of weight loss medications after bariatric surgery for weight regain or inadequate weight loss.
        Surg Obes Relat Dis. 2019; 15: 128-132